Illumina, Inc. logo ILMN - Illumina, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 25
HOLD 18
SELL 6
STRONG
SELL 0
| PRICE TARGET: $156.27 DETAILS
HIGH: $200.00
LOW: $122.00
MEDIAN: $155.00
CONSENSUS: $156.27
DOWNSIDE: 17.84%

Stock News

Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Jul 09, 2026 12:05 PM • prnewswire.com
Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat

Illumina: While You Chased AI, This Healthcare Stock Built A $30B Moat

Illumina commands 90%+ market share in genomics sequencing, powering a $30B+ TAM growing at double digits with a robust razor-and-blades model. Post-GRAIL, management's renewed focus on core sequencing, cost control, and capital return is driving revenue recovery, margin expansion, and free cash flow. NovaSeq X placements and consumables pull-through are key near-term catalysts; 65%+ of consumables revenue is clinical, supporting high margins and recurring cash flows.

Jul 09, 2026 07:07 AM • seekingalpha.com
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world.

Jul 09, 2026 05:05 AM • prnewswire.com
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights.

Jun 08, 2026 05:15 AM • prnewswire.com

Price Targets